Venture Partner at Samsara BioCapital
View Live Interactive Profile →Marcos Milla, Ph.D. is a Venture Partner at Samsara BioCapital. His stated experience covers drug discovery in autoimmunity and inflammation, neurosciences and pain, immuno-oncology, and orphan diseases impacting the airway. He was Chief Scientific Officer of Synthorx from 2017 until its acquisition by Sanofi in January 2020, when he became its Head. Earlier he held industry and faculty appointments at GlaxoSmithKline (1995 to 1998), the Perelman School of Medicine of the University of Pennsylvania (1998 to 2005), Roche Palo Alto (2005 to 2009), Janssen R&D (2009 to 2016) and Adaptive Biotechnologies (2016 to 2017). He graduated with a B.S. from Universidad Peruana Cayetano Heredia in 1985 and a Ph.D. in Cell and Molecular Biology from Saint Louis University in 1990, with post-doctoral training at MIT as a Jane Coffin Childs Fellow from 1990 to 1993 and at Duke from 1993 to 1995. Since 2018 he has also held an Adjunct Faculty appointment at the Skaggs School of Pharmacy and Pharmaceutical Sciences of UCSD. Samsara's team page does not state the year he joined the firm.